Document 0275
 DOCN  M94A0275
 TI    Treatment of oropharyngeal candidiasis in HIV-positive patients.
 DT    9412
 AU    Greenspan D; Department of Stomatology, University of California San
       Francisco; 94143-0422.
 SO    J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S51-5. Unique Identifier :
       AIDSLINE MED/94358249
 AB    Most HIV-positive patients develop some form of oral candidiasis, most
       commonly pseudomembranous candidiasis, erythematous candidiasis, or
       angular cheilitis, at some point in their disease. All these
       manifestations are important risk markers for disease progression. Oral
       candidiasis is generally caused by Candida albicans. Although oral
       candidiasis can occur at any stage of HIV infection, it is most common
       in patients with low CD4 counts. Numerous oral and systemic therapies
       are used to treat oral candidiasis, the most popular of which are
       nystatin (topical), clotrimazole (topical), ketoconazole (systemic),
       fluconazole (systemic), and itraconazole (systemic). The topical agents
       are available in assorted dosage forms with varying degrees of efficacy
       and patient acceptability. The limited data currently available suggest
       an advantage for the systemic agents, although problems with resistance
       may limit the usefulness of fluconazole. The efficacy, safety, and cost
       effectiveness of a given agent must be considered when prescribing a
       specific agent for the treatment of oral candidiasis.
 DE    Administration, Oral  Administration, Topical  Antifungal
       Agents/*THERAPEUTIC USE  Candidiasis,
       Oral/*COMPLICATIONS/DIAGNOSIS/*DRUG THERAPY/  IMMUNOLOGY
       Clotrimazole/THERAPEUTIC USE  Fluconazole/THERAPEUTIC USE  Human  HIV
       Infections/*COMPLICATIONS  Ketoconazole/THERAPEUTIC USE  Leukocyte Count
       Nystatin/THERAPEUTIC USE  Risk Factors  T4 Lymphocytes/IMMUNOLOGY
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).